scholarly journals Management of relapsed and refractory multiple myeloma: novel agents, antibodies, immunotherapies and beyond

Leukemia ◽  
2017 ◽  
Vol 32 (2) ◽  
pp. 252-262 ◽  
Author(s):  
C S Chim ◽  
S K Kumar ◽  
R Z Orlowski ◽  
G Cook ◽  
P G Richardson ◽  
...  
Keyword(s):  
Multiple Myeloma ◽  
Novel Agents ◽  
Refractory Multiple Myeloma

Novel Agents for Relapsed and/or Refractory Multiple Myeloma

2009 ◽  
Vol 15 (6) ◽  
pp. 485-493 ◽  
Author(s):  
Sheeba K. Thomas ◽  
Tiffany A. Richards ◽  
Donna M. Weber
Keyword(s):  
Multiple Myeloma ◽  
Novel Agents ◽  
Refractory Multiple Myeloma

Treatment of Relapsed or Refractory Multiple Myeloma in the Era of Novel Agents

2012 ◽  
Vol 08 (02) ◽  
pp. 116 ◽  
Author(s):  
Federica Cavallo ◽  
Barbara Lupo ◽  
Antonio Palumbo ◽  
◽  
◽  
...  
Keyword(s):  
Multiple Myeloma ◽  
Early Phase ◽  
Second Generation ◽  
Treatment Strategies ◽  
New Drugs ◽  
Novel Agents ◽  
Refractory Multiple Myeloma ◽  
Appropriate Treatment ◽  
Prolonged Duration ◽  
Practical Guidelines

The introduction of highly effective novel agents has resulted in a significant improvement in the outcomes of patients with multiple myeloma. These agents, namely thalidomide, bortezomib and lenalidomide, have been extensively studied in the relapsed or refractory multiple myeloma (RRMM) setting and are now being increasingly incorporated into upfront treatment strategies. Second-generation novel agents such as carfilzomib and pomalidomide are being tested in early-phase studies, and preliminary results are encouraging. However, to date, there are no practical guidelines to help physicians choose the best approach for the treatment of RRMM, and direct comparisons between therapies at relapse are warranted. Moreover, despite the recent steps forward in the treatment of multiple myeloma, this disease remains incurable. This article provides an overview of the main studies incorporating novel agents as well as second-generation new drugs for the treatment of RRMM, and may guide physicians in the choice of the most appropriate treatment, associated with prolonged duration of remission and enhanced survival.

scholarly journals The use of novel agents in the treatment of relapsed and refractory multiple myeloma

Leukemia ◽  
2009 ◽  
Vol 23 (12) ◽  
pp. 2222-2232 ◽  
Author(s):  
J P Laubach ◽  
A Mahindra ◽  
C S Mitsiades ◽  
R L Schlossman ◽  
N C Munshi ◽  
...  
Keyword(s):  
Multiple Myeloma ◽  
Novel Agents ◽  
Refractory Multiple Myeloma

scholarly journals Correction: Management of relapsed and refractory multiple myeloma: novel agents, antibodies, immunotherapies and beyond

Leukemia ◽  
2019 ◽  
Vol 33 (4) ◽  
pp. 1058-1059 ◽  
Author(s):  
C. S. Chim ◽  
S. K. Kumar ◽  
R. Z. Orlowski ◽  
G. Cook ◽  
P. G. Richardson ◽  
...  
Keyword(s):  
Multiple Myeloma ◽  
Novel Agents ◽  
Refractory Multiple Myeloma

scholarly journals Treatment strategies in relapsed and refractory multiple myeloma: a focus on drug sequencing and ‘retreatment’ approaches in the era of novel agents

Leukemia ◽  
2011 ◽  
Vol 26 (1) ◽  
pp. 73-85 ◽  
Author(s):  
B Mohty ◽  
J El-Cheikh ◽  
I Yakoub-Agha ◽  
H Avet-Loiseau ◽  
P Moreau ◽  
...  
Keyword(s):  
Multiple Myeloma ◽  
Treatment Strategies ◽  
Novel Agents ◽  
Refractory Multiple Myeloma

Successful Salvage and Hematopoietic Reconstitution with Bortezomib and Melphalan in Relapsed and Refractory Multiple Myeloma

Blood ◽  
2008 ◽  
Vol 112 (11) ◽  
pp. 5209-5209
Author(s):  
Amitabha Mazumder ◽  
Sundar Jagannath ◽  
David H. Vesole
Keyword(s):  
Stem Cells ◽  
Multiple Myeloma ◽  
Clinical Trials ◽  
Stem Cell ◽  
Novel Agents ◽  
High Dose ◽  
Hematopoietic Stem ◽  
Refractory Multiple Myeloma ◽  
Hematopoietic Reconstitution ◽  
Duration Of Response

Abstract The management of relapsed and refractory multiple myeloma (RRMM) patients who have failed older conventional and more recent novel agents remains challenging. Patients typically have short response duration, develop prolonged cytopenias and are usually not eligible for clinical trials due to inadequate bone marrow reserve. Furthermore, these patients often have inadequate numbers of stem cells (<3 × 10(6) CD34/kg) remaining for a myeloablative transplant. In patients who have remaining stem cells in storage, we have developed an algorithm to enable the reconstitution of hematopopiesis to allow enrollment in clinical trials. In addition, our algorithm tests the synergy of bortezomib and non-myeloablative doses of melphalan with stem cell boost support. We have treated 6 patients with RRMM who have failed novel agents (including bortezomib) and chemotherapy (dexamethasone, cytoxan, etoposide, cisplatin, and doxil) and who have had limited duration of response previously with high dose melphalan. All patients were cytopenic (ANC < 1000 and/or platelets < 50,000/mcl) and thus not eligible for existing clinical trials. The melphalan was administered intravenously at 30–50 mg/m2 on days 1 and 4, dependent on the patient age and performance status. Bortezomib was administered 1.3 mg/m2 by intravenous push prior to the melphalan on the same schedule. The patients then received 1.5 to 2.2 × 10(6) CD34+ cells/kg. (depending upon the amount of remaining stem cells). All patients were treated in the outpatient clinic. 3 patients required hospitalization for neutropenic fever; the median hospitalization duration was 3 days (range 0 to 6). The overall response (MR, PR, VGPR) was 100% including: 5 PR and 1 VGPR.. More importantly, all patients achieved improved hematopoiesis with WBC > 2000 and platelets > 50,000/mcl. The median duration of response exceeded 2 months. All patients were able to proceed on to new clinical trials. We conclude that the combination of bortezomib and melphalan produces an effective salvage strategy, with hematopoietic reconstitution in RRMM. This non-myeloablative approach serves as a bridge for disease control and hematopoietic reconstitution to allow for subsequent eligibility on clinical trials. We recommend that during stem cell collection that sufficient hematopoietic stem cells be stored to support future myeloablative and similar non-myeloablative chemotherapy regimens.

scholarly journals Belantamab mafodotin in combination with novel agents in relapsed/refractory multiple myeloma: DREAMM-5 study design

2021 ◽  
Author(s):  
Ajay K Nooka ◽  
Katja Weisel ◽  
Niels WCJ van de Donk ◽  
David Routledge ◽  
Paula Rodriguez Otero ◽  
...  
Keyword(s):  
Multiple Myeloma ◽  
Mechanisms Of Action ◽  
Novel Agents ◽  
Gamma Secretase ◽  
Antibody Drug Conjugate ◽  
Clinical Trial Registration ◽  
Refractory Multiple Myeloma ◽  
Secretase Inhibitor ◽  
Combination Studies ◽  
Ongoing Phase

Belantamab mafodotin (belamaf) is a BCMA-targeted antibody–drug conjugate recently approved as monotherapy for adults with relapsed/refractory multiple myeloma who have received ≥4 prior therapies. Belamaf binds to BCMA and eliminates myeloma cells by multimodal mechanisms of action. The cytotoxic and potential immunomodulatory properties of belamaf have led to novel combination studies with other anticancer therapies. Here, we describe the rationale and design of DREAMM-5, an ongoing Phase I/II platform study evaluating the safety and efficacy of belamaf combined with novel agents, including GSK3174998 (OX40 agonist), feladilimab (an ICOS; GSK3359609), nirogacestat (a gamma-secretase inhibitor; PF-03084014) and dostarlimab (a PD-1 blocker) versus belamaf monotherapy for patients with relapsed/refractory multiple myeloma. Clinical trial registration: NCT04126200  (ClinicalTrials.gov).

DCEP for relapsed or refractory multiple myeloma after therapy with novel agents

2013 ◽  
Vol 93 (1) ◽  
pp. 99-105 ◽  
Author(s):  
Silvia Park ◽  
Su Jin Lee ◽  
Chul Won Jung ◽  
Jun Ho Jang ◽  
Seok Jin Kim ◽  
...  
Keyword(s):  
Multiple Myeloma ◽  
Novel Agents ◽  
Refractory Multiple Myeloma

Treatment of relapsed and refractory multiple myeloma in the era of novel agents

2011 ◽  
Vol 37 (4) ◽  
pp. 266-283 ◽  
Author(s):  
Niels W.C.J. van de Donk ◽  
Henk M. Lokhorst ◽  
Meletios Dimopoulos ◽  
Michele Cavo ◽  
Gareth Morgan ◽  
...  
Keyword(s):  
Multiple Myeloma ◽  
Novel Agents ◽  
Refractory Multiple Myeloma
Sign in / Sign up

Export Citation Format

Share Document